Also trades as: GLENMARK.BO (BSE) · $vol 1M
GLENMARK.NS NSE
Glenmark Pharmaceuticals Limited
1W: -4.1%
1M: -5.6%
3M: +5.4%
YTD: +19.1%
1Y: +15.0%
3Y: +187.3%
5Y: +302.6%
₹2,331.00 ($24.21)
-3.70 (-0.16%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$33.0B
+498.6% ▲
5Y CAGR: +23.9%
Capital Expenditures
$13.6B
-81.1% ▼
5Y CAGR: +11.9%
Free Cash Flow
$19.4B
+223.1% ▲
5Y CAGR: +40.4%
Dividends Paid
$1.4B
-100.2% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$5.3B
-3133.6% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $14.4B | $8.7B | -$15.0B | $14.0B | $13.6B |
| Depreciation & Amort. | $4.9B | $6.1B | $6.3B | $4.9B | $5.7B |
| Stock-Based Comp. | $79M | $68M | $50M | -$92M | $0 |
| Change in Working Capital | -$5.6B | -$10.7B | -$8.0B | -$25.3B | -$4.5B |
| Other Non-Cash Items | -$2.7B | $2.1B | $14.0B | -$1.7B | $18.1B |
| Operating Cash Flow | $11.1B | $6.3B | -$2.7B | -$8.3B | $33.0B |
| — Investing Activities — | |||||
| Capital Expenditures | -$7.9B | -$6.1B | -$9.0B | -$7.5B | -$13.6B |
| Acquisitions (Net) | $113M | $803M | $54.5B | $24M | $23M |
| Investment Purchases | -$400M | -$60M | $0 | $0 | -$2M |
| Investment Sales | $300M | $50M | $71M | $7.5B | $308M |
| Other Investing | $4.6B | -$670K | -$146M | $29M | $480K |
| Investing Cash Flow | -$3.3B | -$5.3B | $45.4B | $21M | -$13.2B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$10.3B | $6.3B | -$31.7B | $12.0B | -$22.5B |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$927M | -$1.4B | -$1.2B | -$704M | -$1.4B |
| Other Financing | -$4.1B | -$5.7B | -$6.2B | -$3.1B | -$1.4B |
| Financing Cash Flow | -$5.2B | -$775M | -$39.1B | $7.9B | -$25.2B |
| Net Change in Cash | $2.7B | $325M | $2.2B | $174M | -$5.3B |
| Cash End of Period | $14.1B | $14.4B | $16.6B | $16.8B | $11.8B |
| Free Cash Flow | $3.2B | $176M | -$11.6B | -$15.8B | $19.4B |